tiprankstipranks
Trending News
More News >
ImageneBio (IMA)
NASDAQ:IMA
US Market
Advertisement

ImageneBio (IMA) AI Stock Analysis

Compare
106 Followers

Top Page

IMA

ImageneBio

(NASDAQ:IMA)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
Ikena Oncology's overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
Positive Factors
Strong Cash Position
A strong cash position provides financial flexibility, allowing Ikena Oncology to invest in R&D and navigate periods of low revenue without immediate liquidity concerns.
Proprietary Platform
Ikena's proprietary platform for targeted oncology treatments positions it to potentially develop breakthrough therapies, offering a competitive edge in the biotech industry.
Low Debt Levels
Low debt levels reduce financial risk and interest obligations, allowing more resources to be allocated towards strategic growth initiatives and R&D.
Negative Factors
Declining Revenues
The absence of revenue growth poses a significant challenge, limiting the company's ability to fund operations and invest in future growth without external financing.
Negative Cash Flow
Negative cash flow indicates ongoing cash burn, necessitating reliance on external funding, which can dilute shareholder value and increase financial risk.
Profitability Challenges
Continuous profitability challenges hinder the company's ability to self-sustain, impacting its long-term viability and attractiveness to investors.

ImageneBio (IMA) vs. SPDR S&P 500 ETF (SPY)

ImageneBio Business Overview & Revenue Model

Company DescriptionClinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
How the Company Makes MoneyIkena Oncology makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include milestone payments, research funding, and potential royalties on successfully developed and marketed drugs. Additionally, Ikena may earn income by out-licensing its drug candidates or technology platforms to other firms within the pharmaceutical industry. The company's revenue is also influenced by its ability to advance its drug candidates through clinical trials, obtain regulatory approvals, and successfully launch products into the market.

ImageneBio Financial Statement Overview

Summary
Ikena Oncology is struggling with profitability and revenue generation, impacting its income and cash flow statements negatively. The balance sheet shows some stability due to strong cash reserves and low debt, but historical negative equity highlights underlying financial challenges. The company needs to improve revenue generation and profitability to enhance financial health.
Income Statement
35
Negative
Ikena Oncology has faced declining revenues over recent years, with a revenue drop to zero in the latest period. The company consistently reports negative EBIT and net income, indicating profitability challenges. The lack of revenue growth and negative margins reflect financial instability.
Balance Sheet
40
Negative
The company maintains a strong cash position relative to its debt, with a low debt-to-equity ratio indicating manageable leverage. However, persistent negative equity in past years points to potential financial distress. The equity ratio has improved, yet the overall balance sheet strength remains modest.
Cash Flow
45
Neutral
Ikena Oncology has improved its free cash flow from prior periods, but it remains negative, indicating continued cash burn. The operating cash flow is negative but has shown improvement, suggesting better cash management. Despite these improvements, reliance on external financing persists.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.009.16M15.62M30.98M9.19M
Gross Profit47.00K-490.00K8.14M13.58M-16.12M-35.65M
EBITDA-41.61M-48.59M-74.40M-70.15M-33.59M-44.22M
Net Income-30.74M-49.23M-68.17M-68.77M-34.12M-44.26M
Balance Sheet
Total Assets126.17M141.51M192.09M172.26M247.88M168.40M
Cash, Cash Equivalents and Short-Term Investments95.64M124.39M175.47M156.95M232.22M162.49M
Total Debt5.68M7.52M10.74M5.69M6.99M186.00K
Total Liabilities10.26M15.58M22.34M25.29M40.00M269.45M
Stockholders Equity115.91M125.93M169.76M146.97M207.88M-101.05M
Cash Flow
Free Cash Flow-29.18M-46.00M-80.16M-75.54M-62.01M-38.59M
Operating Cash Flow-29.18M-46.00M-79.74M-74.11M-60.25M-37.83M
Investing Cash Flow42.80M-34.90M64.14M-99.28M-1.76M2.92M
Financing Cash Flow0.000.0075.98M1.09M131.74M116.18M

ImageneBio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.78
Price Trends
50DMA
12.92
Negative
100DMA
14.12
Negative
200DMA
15.50
Negative
Market Momentum
MACD
-1.53
Negative
RSI
24.53
Positive
STOCH
2.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 7.78 is below the 20-day moving average (MA) of 9.51, below the 50-day MA of 12.92, and below the 200-day MA of 15.50, indicating a bearish trend. The MACD of -1.53 indicates Negative momentum. The RSI at 24.53 is Positive, neither overbought nor oversold. The STOCH value of 2.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.

ImageneBio Risk Analysis

ImageneBio disclosed 80 risk factors in its most recent earnings report. ImageneBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ImageneBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
44
Neutral
68.16M-4.21
44
Neutral
60.47M-0.56-229.80%-98.56%-347.81%
44
Neutral
52.79M-2.6662.69%
41
Neutral
$89.45M-23.76%-100.00%55.32%
36
Underperform
49.07M-0.6918.86%
27
Underperform
71.16M-0.6448.45%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMA
ImageneBio
7.78
-12.86
-62.31%
BYSI
Beyondspring
1.68
-0.37
-18.05%
ACET
Adicet Bio
0.84
-0.56
-40.00%
DTIL
Precision BioSciences
4.93
-4.18
-45.88%
MAIA
MAIA Biotechnology, Inc.
1.57
-1.04
-39.85%
ACRV
Acrivon Therapeutics, Inc.
1.54
-5.72
-78.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025